Article
Author(s):
ICYMI, this week we had stories from the 2022 American College of Mohs Surgery Annual Meeting, bimekizumab's FDA set back, and more.
In a presentation at the current American College of Mohs Surgery meeting, Jennifer G. Powers, MD, highlights the needed improvement for immediate access to skin cancer care for VA patients, noting a 33 day average wait time compared to the VAs optimal goal of 28 days.
Presenters highlight the possible solutions to communication between the scrubbed-in surgery team and outside help that could save time.
A study presented at the current ACMS meeting highlights variables that could predict BCC, including: gender, immune status, and more.
At the current ACMS meeting, Kelsey E. Hirotsu, MD, discussed the bleeding complications seen in patients on ibrutinib for CLL.
Immunotherapy, intralesional treatments, multidisciplinary care teams define rapidly-evolving multimodal approach.
Marty Makary, MD, MPH, predicts systemwide change in the world of health care.
Single-stage periosteal flap technique to treat full-thickness eyelid defects is safe, effective, and aesthetically acceptable, according to a study presented at the 2022 American College of Mohs Surgery Annual Meeting on May 12, 2022.
Topical tranexamic acid is an effective wound care adjunct in reducing rates of postoperative bleeding of granulating defects in Mohs micrographic surgical settings.
Overall, non-melanoma skin cancer (NMSC) visits (all pooled specialties/areas) have been plateauing. However , metropolitan but not rural areas saw an increase in visits where NMSC was the chief complaint. However, the percentage of NMSC in rural areas that is managed by dermatologists and dermatologic surgeons is also on the rise, according to a presentation given at the 2022 American College of Mohs Surgery Annual Meeting.
Sunscreen use is on the rise, but further education is needed.
At the ACMS meeting, Chrysalyne D. Schmults, MD, MScE, highlighted molecular diagnostics for squamous cell carcinoma.
UCB announced the FDA issued a CRL that stated that the FDA cannot approve the BLA in its current form.
A poster presented at the 2022 American College of Mohs Surgery Annual Meeting not only suggested a link between multiple myeloma and a heightened rate of melanoma, but also demonstrated potential for higher overall mortality rates.
Data from one study showed younger women more likely to use sunscreen than older adults.
A survey asked dermatologists whether they had personal treated head and neck melanoma with excision, and if and when they referred patients with melanoma on the head and neck to a Mohs surgeon.
Many patients worry about privacy and accuracy.
Lower household income and requiring multiple medications play large roles.
In this episode, the topics up for discussion include possible technologies to help atopic dermatitis patient adherence with treatment along with new strategies to improve patient experiences at the practice.
Patients with chronic inflammatory skin diseases do not have an increased risk of venous thromboembolism (VTE) compared to a matched healthy control cohort. This knowledge can be useful to clinicians when contemplating systemic immunomodulatory therapies in their dermatologic patients.
In this week’s Pointers with Dr Portela, the 208SkinDoc hosts a podcast called, “Between Two Derms.” This week he covers cases in the clinic, psoriasis at the Met Gala and more.
The risks of certain comorbid conditions varied between the 2 groups of patients.
Lifestyle behaviors, such as body mass index and smoking, were shown to have a stronger association with psoriasis, regardless of genetic risk.
Protection from the harsh rays of the sun is crucial for everyone—including children. Now that summer has arrived, a refresher course for your patients and their families on sun protection, which can go a long way in preventing skin damage and disorders due to the sun.
The Skin Cancer Foundation at its Annual Champions for Change Gala in New York, New York, raised the money while also honoring 157 dermatologists for volunteering with the Foundations skin cancer screening program on May 12.
In 2023 as many as 11 biosimilars to Humira are headed for the US market.
Study shows a marked improvement when medical abbreviations and acronyms are spelled out instead.